Jorveza (Budesonide)

• Budesonide is a locally acting glucocorticoid that targets inflammatory pathways within the gastrointestinal tract, making it useful in the management of inflammatory bowel disease.
• Crohn's disease (mild to moderate): oral suspension of budesonide reduces mucosal inflammation, induces clinical remission, and helps maintain symptom control in adult patients, thereby improving daily functioning and reducing the need for systemic steroids.
• Maintenance therapy in Crohn's disease: continued use of the oral suspension after induction helps sustain remission, limits disease flare-ups, and may reduce dependence on higher‑dose systemic corticosteroids.

• Budesonide exerts its anti‑inflammatory effect by binding to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This interaction suppresses pro‑inflammatory cytokines such as IL‑1, IL‑6, and TNF‑α, while up‑regulating anti‑inflammatory proteins, leading to reduced leukocyte infiltration and stabilization of the intestinal mucosal barrier. The high first‑pass metabolism in the liver limits systemic exposure, allowing high local concentrations in the gut with fewer systemic side effects compared with conventional corticosteroids.

Budesonide oral suspension may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Headache
• Abdominal pain
• Oral candidiasis

Serious or Rare Side Effects

• Adrenal suppression
• Severe infections
• Hypersensitivity reactions (rash, angioedema)
• Osteoporosis with long‑term use

When prescribing Jorveza, clinicians should consider several safety measures.

• Monitor adrenal function: assess for signs of insufficiency during and after therapy.
• Evaluate infection risk: avoid use in active systemic infections.
• Assess bone health: consider calcium/vitamin D supplementation for long‑term treatment.
• Use with caution in hepatic impairment: reduced metabolism may increase systemic exposure.
• Do not discontinue abruptly: taper dose to prevent withdrawal symptoms.
• Store at room temperature: keep in original container, protect from moisture and light.

Budesonide can interact with other medicines, requiring attention to potential changes in efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic budesonide levels.
• Rifampin or other CYP3A4 inducers: may reduce therapeutic effect.
• Live vaccines: immunosuppression can increase risk of infection.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive gastrointestinal irritation.
• Anticoagulants (warfarin): potential for altered bleeding risk.
• Diuretics: may enhance hypokalemia when combined with systemic corticosteroid effects.